DocSym
β
Searchsearch
Search
(G13.1*) Other systemic atrophy primarily affecting central nervous system in neoplastic disease
More details coming soon
NaN% mortality rate associated with the disease other systemic atrophy primarily affecting central nervous system in neoplastic disease
Diagnosis other systemic atrophy primarily affecting central nervous system in neoplastic disease is diagnosed Prevalent in Women Only
0
Men receive the diagnosis other systemic atrophy primarily affecting central nervous system in neoplastic disease
0 (No mortality)Died from this diagnosis.
100
95
90
85
80
75
70
65
60
55
50
45
40
35
30
25
20
15
10
5
0
0
Women receive the diagnosis other systemic atrophy primarily affecting central nervous system in neoplastic disease
0 (No mortality)Died from this diagnosis.
Risk Group for the Disease other systemic atrophy primarily affecting central nervous system in neoplastic disease - Men and Women aged 0
No Cases of the Disease Other systemic atrophy primarily affecting central nervous system in neoplastic disease identified in Men
Less common in men the disease occurs at Age 0-95+Less common in women the disease occurs at Age 0-95+
No Cases of the Disease Other systemic atrophy primarily affecting central nervous system in neoplastic disease identified in Men
Disease Features other systemic atrophy primarily affecting central nervous system in neoplastic disease
Absence or low individual and public risk
Other systemic atrophy primarily affecting central nervous system in neoplastic disease - what does this mean
Other systemic atrophy primarily affecting the central nervous system in neoplastic disease is caused by the abnormal growth of cancerous cells in the nervous system, which can lead to damage of the brain, spinal cord and other parts of the nervous system. this can cause a range of symptoms, including weakness, paralysis, loss of sensation, and difficulty with coordination and balance.
What happens during the disease - other systemic atrophy primarily affecting central nervous system in neoplastic disease
Other systemic atrophy primarily affecting the central nervous system in neoplastic disease is caused by an accumulation of abnormal proteins in the brain and spinal cord, leading to the death of nerve cells. the accumulation of these proteins can be caused by a variety of factors, including genetic mutations, environmental exposures, and certain medications. as these proteins accumulate, they can cause a range of symptoms, including progressive muscle weakness, cognitive decline, and difficulty with coordination and balance.
Clinical Pattern
More details coming soon
How does a doctor diagnose
- Complete physical examination
- Neurological examination
- CT scan of the brain
- MRI of the brain
- Spinal tap
- Blood tests
- Urine tests
- Electroencephalogram (EEG)
- Electromyography (EMG)
- Genetic testing
- Biopsy of affected tissue
Treatment and Medical Assistance
Main Goal: To reduce the symptoms of the neoplastic disease and improve the quality of life for the patient.
- Medications to reduce inflammation and pain
- Physical therapy to improve strength and mobility
- Occupational therapy to improve daily functioning
- Speech therapy to improve communication
- Counseling to help with emotional and psychological issues
- Nutritional counseling to improve dietary needs
- Exercise programs to improve cardiovascular health
- Assistive devices to improve safety and independence
No Hospitalization Required
Average Time for Outpatient Care Not Established
Other systemic atrophy primarily affecting central nervous system in neoplastic disease - Prevention
The prevention of other systemic atrophy primarily affecting the central nervous system in neoplastic diseases can be accomplished by maintaining a healthy lifestyle, avoiding smoking and excess alcohol consumption, and getting regular medical check-ups to detect any early signs of the disease. additionally, it is important to be aware of any risk factors for developing the disease, such as family history or exposure to certain environmental hazards, and to take steps to reduce those risks.